First Gene Therapy Trial for Unborn Babies Gets Closer

For a quarter century, doctors have dreamed of fixing genetic disorders before a baby is even born. That dream just took its biggest leap forward yet.

UCSF surgeon Tippi MacKenzie has submitted an application to the FDA for the first gene therapy trial treating patients still in the womb. If approved, the trial would treat five babies with a rare genetic disorder called lysosomal storage disease.

MacKenzie started working on this idea back in the early 2000s as a young researcher. She and her team successfully cured mice with hemophilia and other inherited diseases using gene replacement therapy before birth. Everyone told her human trials were just five years away.

Twenty five years later, she's finally there. The breakthrough came when the FDA reviewed her team's proposal and delivered unexpected news. They could skip the usual animal testing phase entirely.

The reason? The gene therapy vector MacKenzie plans to use has already been tested so thoroughly by other researchers treating children and adults. Its safety profile is well understood, which means the path to helping these tiny patients just got much shorter.

The Ripple Effect

This trial represents more than just five families getting hope. It opens the door to treating genetic diseases at the earliest possible moment, when a developing baby's cells are still forming and most receptive to change.

Gene therapy before birth could one day treat dozens of inherited disorders that currently have no cure. Catching these diseases in the womb means babies could be born healthy instead of facing a lifetime of treatments, hospital visits, and complications.

The timing matters too. Gene therapy technology has matured dramatically over the past decade. What seemed impossible when MacKenzie started is now backed by proven science and real world results in older patients.

MacKenzie's persistence through 25 years of waiting shows how medical breakthroughs really happen. Not in sudden eureka moments, but through decades of careful work, failed experiments, and refusing to give up on an idea that could change lives.

The FDA's decision to fast track the review process by waiving animal studies signals confidence in both the science and the urgent need. Families dealing with these devastating genetic disorders finally have reason for real hope.

Five babies will be the first, but they won't be the last to benefit from treating disease at life's very beginning.